Last updated: February 28, 2026
What is the drug identified by NDC 00310-0283?
NDC 00310-0283 refers to Vasculotide, an investigational agent classified as a vascular-targeting peptide or angiopoietin modulator. While not yet approved for widespread clinical use, Vasculotide has demonstrated potential in preclinical and early-phase clinical trials for conditions involving vascular leakage, such as sepsis, acute respiratory distress syndrome (ARDS), and other inflammatory states.
Current Market Environment
Regulatory Status
As of 2023, Vasculotide maintains an investigational status with no FDA approval. It is under development by a biotech firm, with clinical trials ongoing to establish safety and efficacy in targeted indications. No formal pricing or commercial distribution exists at this stage.
Clinical Trial Pipeline
- Phase 1 completed in 2022 with favorable safety profile.
- Phase 2 trials initiated in late 2022 for sepsis-related vascular leakage.
- Pending additional trial results, future approval prospects remain uncertain.
Competitive Landscape
| Company |
Product |
Stage |
Indications |
Regulatory Status |
| Vasculotide Biotech |
Vasculotide |
Phase 2 |
Sepsis, ARDS |
Investigational |
| Ang1 Mimetic |
ANG-100 |
Preclinical |
Vascular leakage |
Preclinical |
| Receptor-targeted Agents |
Various |
Early-stage |
Endothelial dysfunction |
Clinical Trials |
Key competitors are anti-angiogenic therapies and other vascular stabilizers, such as angiopoietin-1 mimetics and Tie2 receptor modulators.
Market Size Estimates
- Global sepsis treatment market: US$11 billion in 2022.
- ARDS market (including Covid-related cases): US$3.8 billion in 2022.
- Projected compounded annual growth rate (CAGR) from 2022-2027: approximately 7.2%.
Given Vasculotide’s targeted indications, its potential market penetration initially would be limited to intensive care units (ICUs) with an addressable patient population of approximately 3–5 million globally.
Pricing Assumptions
- Without formal approval, pricing remains theoretical.
- Similar biologics (e.g., anti-VEGF therapies): US$2,000–$5,000 per dose.
- Targeted therapies for critical care: US$3,000–$8,000 per treatment course.
Price Projections
Scenario 1: Early Commercialization (Post-Approval in 2025)
| Parameter |
Assumption |
Estimated Price per Dose |
Estimated Market Penetration |
Revenue Potential |
| Launch Year |
2025 |
US$4,000 |
10% of target population |
US$1.2 billion annually |
| Uptake Rate |
5% in first year, rising |
|
|
|
| Patient Course |
1 dose per patient |
|
|
|
| Total Eligible Patients |
300,000 |
|
|
|
Scenario 2: Mid-term Growth (Post-2027)
| Parameter |
assumption |
Estimated Price per Dose |
Expected Penetration |
Revenue Estimate |
| Market Expansion |
10-15% of ICU patients |
US$4,500 |
20-30% of target population |
US$3.3 billion annually |
Risks to Price and Market
- Regulatory delays or failure to achieve approval.
- Competition from existing therapies or new entrants.
- Cost of production limiting margin potential.
- Payer coverage and reimbursement landscape in critical care.
Key Revenue Drivers
- Efficacy demonstrating reduction in vascular leakage and mortality.
- Favorable safety profile allowing broad ICU adoption.
- Rapid scalability given the injectable biologic nature.
Market Entry Barriers
- Long development timelines typical in biologic drugs.
- High clinical trial costs due to critical illness populations.
- Regulatory scrutiny for ICU interventions.
- Need for clear differentiation from existing treatments.
Summary
Vasculotide represents an early-stage pipeline candidate with potential in critical care, especially for sepsis and ARDS. Its commercial value hinges on successful clinical outcomes and regulatory approval. Price points could approximate US$3,000–$8,000 per dose post-approval, aligned with comparable biologic therapies targeting acute conditions. Market penetration could reach tens of thousands of patients annually within the first five years of launch, translating to revenue potential in the billion-dollar range if clinical and regulatory milestones are achieved.
Key Takeaways
- Neither FDA approval nor commercial distribution exists for NDC 00310-0283 as of 2023.
- Market size in sepsis and ARDS is large; total addressable market could reach US$15 billion globally.
- Price projections range from US$3,000–$8,000 per dose, with full market penetration achievable in late-stage development.
- Clinical success and regulatory approval are critical to realizing revenue.
- Competition is limited but includes other vascular stabilizers and biologics under development.
FAQs
-
When might Vasculotide gain regulatory approval?
Likely in 2025–2026, contingent on positive Phase 3 trial results and regulatory review timelines.
-
What factors influence its market pricing?
Efficacy, safety profile, manufacturing costs, competition, and payer reimbursement policies.
-
Who are the primary competitors?
Anti-angiogenic agents, endothelial stabilizers, and newer biologics targeting vascular leakage.
-
What are the primary indications?
Sepsis, ARDS, and possibly other vascular leakage syndromes in critical care.
-
What risks could impact its market potential?
Clinical failure, regulatory setbacks, high development expenses, or adverse payer policies.
References
[1] MarketWatch. (2023). Sepsis treatment market analysis.
[2] EvaluatePharma. (2022). Biologic drugs in critical care market reports.
[3] FDA. (2022). Guidance for Industry: Clinical Trials for Vascular Agents.
[4] PwC. (2022). Biotech pricing and reimbursement trends.
[5] Statista. (2022). Global ARDS and sepsis market size estimates.
